1.
|
Phase: Phase IV Type: Diagnostic, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: COLOGEN, NCT00138060
|
|
2.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
3.
|
Phase: Phase IV Type: Diagnostic, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: KA05030-MA, KA05030, NCT00300547
|
|
4.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: 01-07, NCT00535652
|
|
5.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CHUL-BIO-COLON, RECF0356, INCA-RECF0356, NCT00559676
|
|
6.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML21380, NCT00577031
|
|
7.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 75 and over Sponsor: Other Protocol IDs: I07028, N° EudraCT : 2008-001195-7, NCT00812864
|
|
8.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2009-03, NCT00868569
|
|
9.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2009-04, NCT00874406
|
|
10.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: AMT/P2GI/001 Part III, LC001Auron2005, NCT00405561
|
|
12.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001C2241, NCT00419159
|
|
13.
|
Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 80 Sponsor: Other Protocol IDs: Flav-Hoe-CCC, NCT00609310
|
|
14.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_529, MK0646-004, NCT00614393
|
|
15.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: STX0206, NCT00724503
|
|
16.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 08-PIR-03, NCT00856375
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NMRC-ICR01, EU-99019, NCT00007930
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-R-04, NCT00058474, CALGB-NSABP-R-04
|
|
19.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: NCRI-FOCUS2, MRC-CR09, EU-20303, NCT00070213
|
|
20.
|
Phase: Phase III Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: FFCD 2000 – 05, CET 815, NCT00126256
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: FRE-FNCLCC-ACCORD-12/0405, EU-20522, NCT00227747
|
|
22.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SWS-SAKK-40/04, EU-20528, NCT00238381
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: JCOG0404, C000000105, NCT00147134
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRE-2002.445-T, NCT00164879
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: HGCSG-CAD, NCT00209742
|